New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

This Is Us star Chrissy Metz reflects on her struggles with her body image and self-worth, and shares her thoughts on weight ...

Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...

NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Ozempic users who suffer strokes appear to have much lower death rates and better long-term survival. Evidence points to a ...